07:00 , Apr 16, 2012 |  BC Week In Review  |  Financial News

BioRelix completes venture financing

BioRelix Inc. , New Haven, Conn.   Business: Infectious   Date completed: 4/3/12   Type: Venture financing   Raised: $269,160   Investor: Connecticut Innovations   Note: Connecticut Innovations said the funding is part of a...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

BioRelix, Merck deal

The companies partnered to discover and develop antibacterial drug candidates. BioRelix will screen compounds from Merck's library against proprietary bacterial RNA targets using the biotech's riboswitch technology. The partners will jointly conduct preclinical research, after...
23:49 , Oct 4, 2010 |  BC Extra  |  Company News

BioRelix, Merck in antibacterial discovery deal

BioRelix Inc. (New Haven, Conn.) partnered with Merck & Co. Inc. (NYSE:MRK) to discover and develop antibacterial drug candidates. BioRelix will screen compounds from Merck's library against proprietary bacterial RNA targets using its riboswitch technology....
07:00 , Apr 6, 2009 |  BC Week In Review  |  Company News

BioRelix, Dalton Chemical Laboratories Inc. deal

The partners expanded and renewed a 2007 deal under which Dalton is designing and synthesizing compounds against riboswitch targets from BioRelix. Terms were not disclosed. BioRelix is developing anti-infectives that target bacterial riboswitches. Riboswitches are...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Company News

BioRelix, University of Colorado deal

The university granted BioRelix an exclusive, worldwide license to IP covering undisclosed riboswitch technology. According to the university, BioRelix has a previous license to another riboswitch technology, and a license through Yale University to riboswitch...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

BioRelix, Dalton Chemical Laboratories Inc. deal

Dalton will design and synthesize compounds against undisclosed RiboSwitch bacterial RNA targets from BioRelix. BioRelix will further develop the compounds as anti-infectives. RiboSwitches are short sections of RNA that control esssential bacterial cell functions. Further...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Company News

BioRelix board of directors update

BioRelix Inc. , New Haven, Conn.   Business: Infectious   Appointed: Philippe Chambon, managing director at New Leaf Venture Partners; Dov Goldstein, principal at Aisling Capital; and Campbell Murray, managing director at Novartis Venture Fund...
00:15 , Jun 9, 2007 |  BC Extra  |  Financial News

BioRelix raises $25.8 million

BioRelix (New Haven, Conn.) raised $25.8 million in a series A round led by CHL Medical Partners. New investors New Leaf Venture and Aisling joined existing investors Novartis Venture Fund; Elm Street Ventures; and Alexandria...